revealed that Treg cells inhibit the response of effector CD4+ T cells, conventional proinflammatory T (Tconv) cells by inhibiting conventional type 2 dendritic cells (cDCs).[117] This discovery highlights the role of cDCs in the initiation of the anti‐tumor response mediated by Tconv, which may become a novel hotspot in anti‐tumor immunity studies. Here, CD4 is linked to neoplasm.